Literature DB >> 22723463

The structural basis for serotype-specific neutralization of dengue virus by a human antibody.

Ee Ping Teoh1, Petra Kukkaro, En Wei Teo, Angeline P C Lim, Tze Tong Tan, Andy Yip, Wouter Schul, Myint Aung, Victor A Kostyuchenko, Yee Sin Leo, Soh Ha Chan, Kenneth G C Smith, Annie Hoi Yi Chan, Gang Zou, Eng Eong Ooi, D Michael Kemeny, Grace K Tan, Jowin K W Ng, Mah Lee Ng, Sylvie Alonso, Dale Fisher, Pei-Yong Shi, Brendon J Hanson, Shee-Mei Lok, Paul A MacAry.   

Abstract

Dengue virus (DENV) is a mosquito-borne flavivirus that affects 2.5 billion people worldwide. There are four dengue serotypes (DENV1 to DENV4), and infection with one elicits lifelong immunity to that serotype but offers only transient protection against the other serotypes. Identification of the protective determinants of the human antibody response to DENV is a vital requirement for the design and evaluation of future preventative therapies and treatments. Here, we describe the isolation of a neutralizing antibody from a DENV1-infected patient. The human antibody 14c10 (HM14c10) binds specifically to DENV1. HM14c10 neutralizes the virus principally by blocking virus attachment; at higher concentrations, a post-attachment step can also be inhibited. In vivo studies show that the HM14c10 antibody has antiviral activity at picomolar concentrations. A 7 Å resolution cryoelectron microscopy map of Fab fragments of HM14c10 in a complex with DENV1 shows targeting of a discontinuous epitope that spans the adjacent surface of envelope protein dimers. As found previously, a human antibody specific for the related West Nile virus binds to a similar quaternary structure, suggesting that this could be an immunodominant epitope. These findings provide a structural and molecular context for durable, serotype-specific immunity to DENV infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22723463     DOI: 10.1126/scitranslmed.3003888

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  127 in total

1.  Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.

Authors:  Rajendra Raut; Kizzmekia S Corbett; Rashika N Tennekoon; Sunil Premawansa; Ananda Wijewickrama; Gayani Premawansa; Piotr Mieczkowski; Claudia Rückert; Gregory D Ebel; Aruna D De Silva; Aravinda M de Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-05       Impact factor: 11.205

2.  Dengue virus: Bumps in the road to therapeutic antibodies.

Authors:  Leslie Goo; Theodore C Pierson
Journal:  Nature       Date:  2015-08-20       Impact factor: 49.962

3.  Structural Mimicry of the Dengue Virus Envelope Glycoprotein Revealed by the Crystallographic Study of an Idiotype-Anti-idiotype Fab Complex.

Authors:  Yee Hwa Wong; Boon Chong Goh; She Yah Lim; En Wei Teo; Angeline P C Lim; Pete C Dedon; Brendon J Hanson; Paul A MacAry; Julien Lescar
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

4.  Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry.

Authors:  Zhiqiang Ku; Xiaohua Ye; Jinping Shi; Xiaoli Wang; Qingwei Liu; Zhong Huang
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

Review 5.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.

Authors:  Aravinda M de Silva; Eva Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

6.  Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus.

Authors:  James D Brien; Soila Sukupolvi-Petty; Katherine L Williams; Chia-Ying Kao Lam; Michael A Schmid; Syd Johnson; Eva Harris; Michael S Diamond
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

7.  An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Authors:  Akane Urakami; Mya Myat Ngwe Tun; Meng Ling Moi; Atsuko Sakurai; Momoko Ishikawa; Sachiko Kuno; Ryuji Ueno; Kouichi Morita; Wataru Akahata
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

8.  Broad and strong: the ultimate antibody to dengue virus.

Authors:  Josefina Coloma; Eva Harris
Journal:  Nat Immunol       Date:  2015-02       Impact factor: 25.606

9.  Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.

Authors:  Laura Rivino; Emmanuelle A P Kumaran; Vojislav Jovanovic; Karen Nadua; En Wei Teo; Shyue Wei Pang; Guo Hui Teo; Victor Chih Hao Gan; David C Lye; Yee Sin Leo; Brendon J Hanson; Kenneth G C Smith; Antonio Bertoletti; David M Kemeny; Paul A MacAry
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

10.  Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.

Authors:  Scott A Smith; Ruklanthi de Alwis; Nurgun Kose; Anna P Durbin; Stephen S Whitehead; Aravinda M de Silva; James E Crowe
Journal:  J Infect Dis       Date:  2013-03-22       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.